logo
  

AstraZeneca: FDA Grants Priority Review For Imfinzi - Quick Facts

AstraZeneca plc (AZN.L,AZN) announced the US FDA has accepted a supplemental Biologics License Application and granted Priority Review for Imfinzi for the treatment of patients with previously untreated extensive-stage small cell lung cancer. The sBLA was based on positive results from the Phase III CASPIAN trial. The PDUFA date is set for the first quarter of 2020.

Imfinzi is approved in the curative-intent setting of unresectable, Stage III non-small cell lung cancer after chemoradiation therapy in 54 countries, including the US, Japan and the EU.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Freshpet Inc. is recalling a single lot of Freshpet Select Small Dog Bite Size Beef & Egg Recipe Dog Food citing the potential contamination with Salmonella, a bacterium, the U.S. Food and Drug Administration said. The product comes in 1 LB bags, with UPC code of 627975012939, lot code of 1421FBP0101 and sell by date of 10/30/2021. Google has revoked its three-year ban on cryptocurrency-related ads on its sites under the search giants' new ad services policy. This action will now allow cryptocurrency exchanges and wallets certified by Google to advertise their products and services on Google's network, beginning August 3, 2021. The UK's competition regulator said Friday that it has secured commitments from Google to address concerns about the tech giant's proposal to remove third-party cookies from Chrome browser.
Follow RTT